Final O'Neill Review Suggests Supra-National AMR Body & Pharma Levy
Executive Summary
Antimicrobial Resistance (AMR) is a huge economic and security threat necessitating immediate coordinated action and pooled funding by a global coalition of governments, institutions, companies and NGOs, Jim O'Neill says in his review's final report on the topic, which outlines a menu of options for accomplishing that – including a levy on the pharma sector – and says a supra-national entity will also be needed to tackle AMR.
You may also be interested in...
Wellcome Trust Makes AMR Strategic Priority After Funding O'Neill Review
Britain's well-endowed and influential Wellcome Trust which co-funded the O'Neill Review on how to tackle antimicrobial resistance has now made AMR one of its strategic priorities and aims to raise its profile with it. Wellcome policy head Ed Whiting outlines next steps in an interview with the Pink Sheet.
Jim O’Neill Is “Free For Global AMR Role” After Leaving UK Government
Having suddenly resigned from the UK government, Jim O’Neill says he’s now available to take on a global role, if asked, to promote concrete action on tackling antimicrobial resistance within promised timeframes.
Jim O’Neill Is “Free For Global AMR Role” After Leaving UK Government
Having suddenly resigned from the UK Government Jim O’Neill says he’s now available to take on a global role, if asked, to promote concrete action on tackling antimicrobial resistance within promised timeframes.